Evidence map›Paper›PMID 38868697›Full record

ArticlePCN reports : psychiatry and clinical neurosciences2022

Identification of 22q11.2 deletion in a patient with schizophrenia and clinically diagnosed Rubinstein-Taybi syndrome.

Yasuhito Nagai, Masaki Nishioka, Tatsuki Tanaka, Takahisa Shimano, Eiji Kirino, Toshihito Suzuki, Tadafumi Kato

Abstract readCase Reports
In one paragraph

Article in PCN reports : psychiatry and clinical neurosciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Yasuhito NagaiDepartment of Psychiatry Juntendo University School of Medicine Tokyo Japan.ORCID 0000-0002-9254-5547
Masaki NishiokaDepartment of Psychiatry Juntendo University School of Medicine Tokyo Japan.
Tatsuki TanakaDepartment of Psychiatry Juntendo University School of Medicine Tokyo Japan.
Takahisa ShimanoDepartment of Psychiatry Nakamura Hospital Yoshikawa Japan.
Eiji KirinoDepartment of Psychiatry Juntendo University School of Medicine Tokyo Japan.ORCID 0000-0001-6806-3313
Toshihito SuzukiDepartment of Psychiatry Juntendo University School of Medicine Tokyo Japan.
Tadafumi KatoDepartment of Psychiatry Juntendo University School of Medicine Tokyo Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Rubinstein-Taybi syndrome (RTS) is a rare autosomal-dominant disease. Almost all cases are sporadic and attributed to de novo variant. Psychotic symptoms in RTS are rare and have been reported in only a few published cases. On the other hand, 22q11.2 deletion syndrome is the most common chromosomal microdeletion in humans. The 22q11.2 deletion is well recognized as a risk factor for schizophrenia. Here, we present a schizophrenic psychosis case clinically diagnosed as RTS but resolved as carrying 22q11.2 deletion by genomic analysis. Case presentation: A 38-year-old Japanese male was admitted to our hospital due to psychotic symptoms. He had been diagnosed with RTS based on physical characteristics at the age of 9 months. On admission, we performed whole exome sequencing. He had no pathogenic variant in Conclusion: The psychiatric manifestation and genomic analysis may be a clue to detecting 22q11.2 deletion syndrome in undiagnosed patients. The reason for similarity in physical characteristics in 22q11.2 deletion syndrome and RTS remains unresolved. The 22q11.2 deletion and

Indexed as

22q11.2 deletion syndromeautism spectrum disorderHERC1Rubinstein–Taybi syndromeschizophrenia

Identifiers

PMID38868697
PMCPMC11114328

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.